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ABSTRACT
Cdc6 is a key regulator of the strict alternation of
S and M phases during the mitotic cell cycle. In
mammalian and plant cells that physiologically
become polyploid, cdc6 is transcriptionally and
post-translationally regulated. We have recently
reported that Cdc6 levels are maintained in mega-
karyoblastic HEL cells, but severely downregulated
by ectopic expression of transcriptional repressor
Drosophila melanogaster escargot. Here, we show
that cdc6 promoter activity is upregulated during
megakaryocytic differentiation of HEL endoreplicat-
ing cells, and that Escargot interferes with such
activation. Transactivation experiments showed
that a 1.7 kb region located at 2800 upstream cdc6
transcription initiation site behaved as a potent
enhancer in endoreplicating cells only. This activity
was mainly dependent on a novel cis-regulatory
element composed by an E2 box overlapping a
GATA motif. Ectopic Escargot could bind this regula-
tory element in vitro and endogenous GATA-1 and
E2A formed specific complexes in megakaryoblastic
cells as well as in primary megakaryocytes.
Chromatin Immunoprecipitation analysis revealed
that both transcription factors were occupying the
E2 box/GATA site in vivo. Altogether, these data
suggest that cdc6 expression could be actively
maintained during megakaryocytic differentiation
through transcriptional mechanisms involving spe-
cific cis- and trans-regulatory elements.
INTRODUCTION
Several terminally differentiated cell lineages, from plants
to mammals, repeatedly enter S phase without completing
mitosis in order to become polyploid (1,2). Among them,
platelet precursors, megakaryocytes, undergo endoreplication
in a process traditionally known as endomitosis. Megakaryo-
cytic polyploidization is believed to be essential for full plate-
let production (3). As in other endoreplicating cells,
megakaryocytic endomitosis is accompanied by a specific
control of G1/S transition cell cycle machinery, which enables
the establishment of such truncated cell cycles (4–7). We have
also recently shown that transcriptional repressor Snail (Sna)
and Escargot (Esg) interfere with the regulation of the G1/S
transition of endomitotic cycles and therefore with polyploi-
dization of megakaryoblastic HEL cells (8). These proteins
also inhibit the entrance into endocycles of embryo and larval
Drosophila cells (9), as well as of mouse trophoblast (10).
However, little is known about the putative targets of these
transcriptional repressors and how they are affecting the es-
tablishment of endomitosis.
We have recently described that Cdc6 is differentially regu-
lated during megakaryocytic polyploidization (11). Cdc6 is
one of the essential factors involved in assembling and licens-
ing origins of replication during the G1 phase of the mitotic
cell cycle [for a review see (12)]. Its expression and ability to
load MCM complex onto the origin of replication are tightly
regulated in the majority of somatic cells to ensure that DNA is
replicated only once per cell cycle (13). Interestingly, cdc6
expression seems to be stabilized not only in megakaryoblastic
cells that undergo endoreplication (11) but also in Arabidopsis
endoreplicating cells (14,15). As also reported in plant cells
(15), what we previously found was that the maintenance of
cdc6 expression during megakaryocytic differentiation could
be achieved through post-translational stabilization in cyclin E
overexpressing cells, and also through transcriptional regula-
tion of cdc6 gene (11).
Cdc6 expression peaks during G1 and is transcriptionally
regulated in an E2F-, cell cycle-related manner, not only in
mammalian (16–18) but also in Drosophila (19) and plant
cells, as is the case of Arabidopsis (14,20). In mammalian
cells, this control is mediated through E2F-2 and E2F-3 bind-
ing to specific sites proximal to the gene transcription initia-
tion site (21,22). In fact, the essential regulatory region
is contained within 300 bp of the 50 flanking region,
where the E2F-binding sites are located (16–18), and no
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further proliferation-mediated transcriptional activity is
obtained by using additional upstream sequences up to
9000 bp (17).
In order to investigate the transcriptional regulation of cdc6
during megakaryoblastic cells endoreplication, we took
advantage of the fact that differentiated Esg-expressing
HEL cells lose their ability to endoreplicate and to express
Cdc6 (11). We have identified potential Esg-binding sites
(E2 boxes) in cdc6 upstream region that could be involved
in maintaining Cdc6 expression during endoreplication and
inhibited by the presence of Esg in HEL cells. We have
found in the 4537 to 2800 region upstream cdc6 transcrip-
tion initiation site three E2 boxes, one of which overlaps a
GATA element. This E2 box/GATA site is the most prominent
binding site, not only for Esg but also for endogenous proteins.
GATA-1 and E2A ‘in vitro’ and ‘in vivo’ occupy this site in
endoreplicating cells. Transactivation data indicate that this
particular sequence may act as an enhancer involved in tran-
scriptional activation of cdc6 promoter only when megakar-
yocytic differentiation is stimulated. The results presented
here suggest that specific transcriptional mechanisms could
be involved in the maintenance of Cdc6 expression that occurs
during megakaryocytic endoreplication.
MATERIALS AND METHODS
Cell culture
Cells were cultured as described previously (8,11). To induce
megakaryocytic or erythrocytic differentiation, 0.15–0.20·106
cells per ml were grown for 48 h in the presence or absence of
108 M o-tetradecanoylphorbol 13 acetate (TPA; Sigma) or
5 · 105 M hemin (Sigma), respectively. For RNA stabiliza-
tion studies, exponentially growing and TPA-treated cells
were cultured for the indicated times in the presence of acti-
nomycin D (5 mg/ml). For proliferation curves, exponentially
growing cells were subcultured into 24-well plates (0.20 · 106
cells per ml and well) with or without TPA. The number of
viable cells was determined by trypan blue exclusion in a
hemocytometer chamber.
Megakaryocyte culture and CD41+ cells
immunoselection
Cord blood (CB) mononucleated cell fraction (MNC) was
obtained after separation on Ficoll-Hypaque gradients and
counted. A total of 5 · 106 cells were used for nuclear extract
isolation. CD34+ cells were isolated from MNC (typically,
5 · 107 cells) using an immunomagnetic procedure (Mini-
MACS, Miltenyi Biotec, Auburn, CA). CB-purified CD34+
cells (5 · 105) were cultured for 12 days in 24-well culture
dishes at 50 000 cells/ml in serum-free medium (CellGro,
CellGenix, Freiburg, Germany) supplemented with recombin-
ant human thrombopoietin [(TPO); non-pegylated; 50 ng/ml;
generously provided by Kirin, Gunma, Japan].
CD41+ cells generated in culture were purified using col-
loidal magnetic dextran iron particles that were selectively
bound to target cells by means of anti-CD41 bi-specific tetra-
meric antibody complexes (StemSep, StemCell Technologies,
Vancouver, BC, Canada). These complexes recognize both
dextran and CD41 surface antigen. Labeled cells were retained
in a column placed in a magnetic field and after washing,
CD41+ cells were eluted from the column, according to the
manufacturer’s instructions.
Plasmids and transfection assays
pHscdc6(4537), a reporter plasmid containing a 4.54 kb frag-
ment of the upstream region of human cdc6 gene inserted into
pGL2Basic (Promega), was kindly provided by Dr Nakamura
(Tokyo Medical and Dental University, Tokyo, Japan) (17).
To construct pHscdc6(2800), a 1.2 kb KpnI/XhoI fragment
and 1.64 kb BamHI/KpnI fragment isolated from pHscdc6luc
were inserted in between the BamHI and XhoI sites of pBlue-
script SK+/ (Stratagene). The resulting construct was digested
with SacI/XhoI to isolate a 2.9 kb fragment that was ligated in
between the SstI and XhoI sites of pGL2Basic. To construct
pHscdc6(1600), 1.6 kb HindIII fragment from pHscdc6Luc
was inserted into the HindIII site of pGL2Basic. To construct
pHscdc6(4537/2800), a 1.7 kb KpnI/BamHI fragment from
pHscdc6(4537) was inserted in between the KpnI/BglII of
pGL2Promoter (Promega). Mutagenesis of the E2 boxes
sites was performed in pHscdc6(4537/2800) using the
Quick Change Method (Quick Change kit, Stratagene
Corp.) by employing the following oligonucleotides:
 To prepare pHscdc6(4537/2800) AM: 50-AGCTGGGAC-
CAAGCTTGTGTACCACT-30; and 50-AGTGGTACACA-
AGCTTGGTCCCAGCT-30.
 To prepare pHscdc6(4537/2800) BM: 50-GTATGAGT-
TAGGAGTTGATAAG-30; and 50-AGGTCCTTATCAA-
CTCCTAACT-30.
 To prepare pHscdc6(4537/2800) BGATAM: 50-GTAT-
GAGTTAGCAGGTGCACAG-30; and 50-AGGTCCTGTG-
CACCTGCTAACT-30.
 To prepare pHscdc6(4537/2800) CM: 50-GAGGCT-
GAGGGGATCCGATCACCTGA-30; and 50-TCAGGTG-
ATCGGATCCCCTCAGCGTC-30.
Cells were transfected by electroporation at 975 mF/250 V in
a 0.4 cm cuvette. A total of 5 · 106 cells were transfected with
5 mg of the various plasmids and 5 mg of renilla plasmid
(Promega). After 5 h, cells were washed with phosphate-
buffered saline (PBS), counted and divided into two aliquots
one of which was treated with TPA. At the end of 48 h following
electroporation, cells were harvested and cell extracts for assay-
ing luciferase activity were prepared using the Dual Luciferase
kit (Promega), according to the manufacturer’s instructions.
Northern blot
Total RNA was extracted using TRIzol1 Reagent (Life Tech-
nologies), following the procedure described by the manu-
facturer. All other conditions, including the source and
preparation of cdc6-specific cDNA probe and the entire
pTRI RNA 28S plasmid, which hybridizes to 28S rRNA
(Ambion, Inc., Austin, TX), were as described previously
(11). The autoradiographs were scanned using a densitometer
(GE-800 Calibrated Densitometer; Bio-Rad) to determine the
relative optical densities of cdc6 mRNA and 28S rRNA
hybridization signals. For each RNA sample, the signal for
the transcripts was measured within the linear range of the
densitometer, and the ratio of cdc6 mRNA signals to 28S
rRNA was calculated.
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Mobility gel shift analysis
EMSA were perfomed as described previously (8) with
0.02 pmol of 32P-labelled oligoprobe and 20 mg of nuclear
extracts. The partially complementary oligonucleotides are as
follows: 50-GCGGCCTGACAGGTGC-30 and 50-CAAAG-
CACCTGTCAGGC-30 (EBE probe); 50-GCTGGGACCA-
CAGGTGTGTAC-30 and 50-AGTGGTACACACCTGTG-
GTCC-30 (BoxA); 50-GTATGAGTTAGCAGGTGATAAG30
and 50-AGGTCCTTATCACCTGCTAACT-30 (BoxB); 50-
GAGGCTGAGGCAGGTGGATCAC-30 and 50- CTCAGGT-
GATCCACCTGCCTCA-30 (BoxC); 50-GTATGAGTTAG-
CAGGTGCACAG-30 and 50-AGGTCCTGTGCACCTGCT-
AACT-30 (BoxB GATAM); 50-GTATGAGTTAGGAGTTGA-
TAAG-30 and 50-AGGTCCTTATCAACTCCTAACT-30
(BoxB EboxM); 50-AATTCGCAGGTGACAGGTGGCAGG-
TGACAGGTGT-30 and 50-CTAGACACCTGTCACCTGC-
CACCTGTCACCTGCG-30 (E2 box tandem).
These were used to generate double-stranded oligoprobes.
Binding reactions were carried out for 20 min at room tem-
perature in binding buffer [20% glycerol, 1 mM DTT, 20 mM
HEPES (pH 7.9), 5 mM MgCl2, 100 mM KCl and 0.2 mM
EDTA] containing 0.02 pmol of 32P-labelled oligoprobe, 20 mg
of protein extracts as indicated, and 40 mg/ml poly(dI-dC).
When needed, competitor oligoprobes were added in excess
to the binding reaction. For supershifts experiments, 2 ml of
anti-GATA-1 (C-20 Santa Cruz), anti-GATA-2 (H-116 Santa
Cruz), anti-E2A (V-18 Santa Cruz) antibodies were incubated
with the nuclear extracts for 2 h at 4C before the addition
of the radiolabelled probe. DNA–protein complexes were
separated from unbound labelled oligoprobes on 6% non-
denaturing polyacrylamide gels in Tris-Borate/EDTA buffer.
After drying, the shifted complexes were visualized using
autoradiography.
Western blot
Nuclear extracts (30 mg) were subjected to SDS–PAGE and
proteins transferred onto BioTrace PVDF membranes (Pall
Corporation, Ann Arbor, MI) for 1 h at 2 mA/cm2 on a semidry
transfer apparatus (Amersham). Ponceau staining was routi-
nely performed on membranes to check sample loading
control. After blocking in PBS containing 0.1% Tween-20
(T-PBS) and 5% skimmed dry milk, filters were incubated
overnight at 4C with anti-human Cdc6 mouse mAb (Ab3;
Oncogene, Darmstadt, Germany) at a 1:500 dilution in T-PBS.
After washing and incubation with goat anti-mouse IgG con-
jugated to horseradish peroxidase (Dako, Glostrup, Denmark),
signals were detected using the enhanced chemiluminescence
system (Pierce, Rockford, IL).
Chromatin immunoprecipitation assays
The procedure was performed as described previously (23),
with the following modifications. Nuclear extracts were soni-
cated with three cycles of 15 s each at 50% maximum power
and 8 mA amplitude with a sonicator (Soniprep 150, MSE),
and Protein-G Sepharose (Oncogene Research Products) was
used instead of Protein-A Sepharose. Incubation with antibod-
ies (anti-GATA-1, rat monoclonal N6 or goat polyclonal C-20,
and anti-E2A, rabbit polyclonal V-18, all from Santa Cruz
Biotechnology) or the corresponding non immune isotype
immunoglobulins (Sigma) was carried out overnight at 4C.
The extracted DNA was resuspended in 30 ml water/107 cells.
An aliquot of 5 ml and the equivalent to 1/1000 of the input
fraction was used for each PCR (40 cycles of 30 s at 94C; 30 s
at 56C; 30 s at 72C and one last cycle of 10 min at 72C),
containing 25 pmol of each upper and lower primers. The
following primers were used:
 For cdc6 E2 box/GATA site: 50-ATTCTGTCTTCTTGT-
GATGGTATTGC-30; and 50-GGTCGTTTAGTTCATGGT-
TAGATTGG-30.
 For cdc6 (2000): 50-TTGTATTTTAGTAGAGACGGG-
GTTTC-30; and 50-GATGGTATTTCTGATGTCTTAG-
TAGG-30.
 For g-globin site: 50-AGAGAAAAACTGGAATGACT-
GAATCG-30; and 50-AAGCGAGTGTGTGGAACTGCT-
GAAGG-30.
PCR products were separated in a 1.5% TBE-agarose gel and
DNA was visualized by Ethidium Bromide staining.
Flow cytometry determinations
Cell surface immunofluorescence staining was performed by
incubating cells at room temperature with the appropriate
dilution in phosphate-buffered saline (PBS)/0.1% NaN3/
10% fetal calf serum (FCS) of anti-human GPIIIa (CD61)
fluorescein isothiocyanate (FITC)-conjugated antibody (Bec-
ton Dickinson) for 20 min. To determine DNA content, cells
were harvested by centrifugation at 500 g for 5 min, washed
in ice-cold PBS and then resuspended in PBS containing
50 mg/ml propidium iodide (PI) and 0.1% Nonidet P-40.
Determination of CD61 expression and cell cycle analysis
were performed using a FACScan analyser using
CELLQUEST software (both from Becton Dickinson).
RESULTS
Constitutive expression of Escargot determines
downregulation of Cdc6 expression at RNA level
We have recently shown that cdc6 expression is stabilized
during megakaryocytic polyploidization but downregulated
in megakaryoblastic cells unable to establish endoreplication
cycles, and among them, HA1 cell line, derived from HEL
cells by constitutive expression of D.melanogaster Esg (11).
We have also shown that ectopic expression of transcriptional
repressor Esg in HEL cells inhibits megakaryocytic endomi-
tosis (8). In this paper, HA1 cells have been designated as
HEL(Esg+) in order to stress that it is the ectopic Esg expres-
sion that differentiates parental and derived cells. Interest-
ingly, Cdc6 protein levels were profoundly diminished in
HEL(Esg+) cells, compared to those in parental HEL cells,
suggesting that Esg could be interfering with cdc6 gene ex-
pression [(11) and Figure 1D]. In an independent search to find
putative Esg targets that could be affecting endoreplication,
we compared cDNAs of endoreplicating HEL and of
HEL(Esg+) cells by DNA microarray hybridization. The ana-
lysis revealed that cdc6 was one of the genes significantly
downregulated in differentiated HEL(Esg+) (N. Vilaboa
and C. Cale´s, unpublished data). To confirm these data, a
northern-blot analysis was carried out to compare the levels
of cdc6 RNA in HEL and HEL(Esg+) after TPA treatment,
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which triggers megakaryocytic differentiation in both cell
lines. We found that cdc6 RNA levels were diminished
after culturing HEL(Esg+) in the presence of TPA (50%),
while a 2-fold induction was reached in differentiated endor-
eplicating HEL cells (Figure 1A). In order to assess whether
cdc6 RNA levels increase in TPA-treated HEL cells was due to
gene transcription maintained or to RNA stabilization, a sim-
ilar experiment was performed in the presence of transcription
inhibitor actinomycin D (ActD). As can be seen in Figure 1B,
as early as 4 h after ActD treatment, cdc6 RNA levels
decreased in untreated HEL and HEL(Esg+) cells. Interest-
ingly, in differentiated HEL cells, the increase obtained
after TPA treatment was not observed for a long period in the
presence of ActD, thus indicating that cdc6 transcription is
indeed active during HEL megakaryocytic differentiation.
Other possibilities that could account for the different cdc6
RNA levels, i.e. a different proliferation state of parental
HEL and Esg-expressing cells, was discarded, as both cell lines
stopped proliferating after TPA treatment [(8) and Figure 1C],
but only parental HEL cells maintain cdc6 expression at RNA
(as shown above) and protein [(11) and Figure 1D) level.
These results also indicate that ectopic expression of Esg
is able to interfere with the mechanisms that determine the
maintenance of cdc6 expression during megakaryocytic poly-
ploidization.
A 1.7 kb cdc6 50-upstream region containing putative
Esg-binding E2 box motifs is responsible for the
reduced cdc6 promoter activation in HEL(Esg+) cells
Esg belongs to the snail family of zinc finger transcriptional
repressors, which function appears to involve binding to E
boxes recognized by a variety of basic helix–loop–helix
(bHLH) transcriptional activators (24). We thus searched a
4537 bp regulatory cdc6 region for putative sites that could
be recognized by ectopic Esg. As shown in Figure 2A, we
found three E2 boxes with perfect match to the described Esg
consensus-binding site A/GCAGGTG, located at 4501 to
4495 (ACAGGTG), 3535 to 3529 (GCAGGTG) and
2995 to 2989 (GCAGGTG) (referred to as Boxes A, B
and C, as indicated). Two other E2 boxes corresponding to
much less specific Esg binding sites (C/TCAGGTG or G/
ACAGNTG) were detected, at 1567 to 1561 (CCAGGTG)
and at 2675 to 2679 (ACAGATG).
Transactivation assays were performed by transfecting
HEL and HEL(Esg+) cells with a construct containing firefly
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Figure 1. cdc6 mRNA levels are downregulated in differentiated HEL(Esg+) cells. (A) HEL and HEL(Esg+) were cultured for 48 h in the absence () or in the
presence (+) of 108 M TPA for 48 h. Total RNA was extracted and analyzed by northern blotting with full-length cdc6 and 28S rRNA-specific cDNA probes.
Quantification of cdc6 mRNA signals normalized by 28S RNA is also shown (dark bars, 3.3 kb specie and light bars, 2.5 kb specie). (B) Cells were cultured as in (A),
and then treated for the indicated times with 5 mg/ml Act D. RNA extraction and analysis was performed as in (A). (C) HEL and HEL(Esg+) cells were seeded in
triplicate wells and cultured in the absence (closed circles) or in the presence (open triangles) of TPA. At the indicated times, cells were harvested and viable cells were
counted as presented in Materials and Methods. (D) Cells were cultured as in (A) and nuclear extracts were isolated, subjected to SDS–PAGE and analyzed by western
blotting with anti-Cdc6 antibody. A portion of total protein staining of transferred gel is shown as a loading control.
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Figure 2. cdc6 upstream region containing Esg-binding E2 boxes is responsible for reduced cdc6 expression in non-endoreplicating cells. (A) Scaled diagram of the
human cdc6 gene showing the E2 boxes with perfect match to Esg consensus binding sites (referred to as Esg-specific E2 Boxes A, B and C) and E2 boxes
corresponding to much less specific Esg binding sites and E2F-binding elements. The arrow indicates the transcription initiation site. Relevant restriction sites are also
shown: X, XhoI; B, BamHI; H, HinDIII; K, KpnI; and B, BglII. (B and C) HEL, HEL(Esg+) and K562cells were transfected with pHscdc6(4537) (B) or
pHscdc6(2800) (C), cultured in the absence or in the presence of TPA or hemin, as indicated, collected and assayed for luciferase activity. (D) HEL, HEL(Esg+) and
K562 and cells were transfected with pHscdc6 (4537/2800), cultured in the absence or in the presence of TPA or hemin, as indicated, collected and assayed for
luciferase activity. The data represent the mean – SD of at least three independent experiments.
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luciferase gene under the control of 4537 to +98 region of
cdc6 upstream region [pHsCdc6–luc(4537), as in (17)]. As
expected, the 4537 to +98 region was able to drive luciferase
expression in exponentially growing cells. However, after
TPA treatment, luciferase activity was significantly increased
in parental HEL but not in differentiated HEL(Esg+) cells.
Such activation was only seen after megakaryocytic differen-
tiation, as the addition of hemin resulted in erythroid differ-
entiation of both HEL and HEL(Esg+). This did not result in
the induction of luciferase activity (Figure 2B). These results
suggest that cdc6 transcriptional activity is induced in endor-
eplicating HEL cells and that Esg may be modulating cdc6
expression by repressing its promoter activity.
We have previously found that cdc6 RNA levels are also
downregulated in megakaryoblastic K562 cells. These cells
respond to TPA, as HEL cells do, in terms of megakaryocytic
differentiation but lack the ability to establish endoreplication
cycles (11). In order to investigate whether increase in cdc6
promoter activity was restricted to endomitotic differentiation,
pHsCdc6–luc(4537) construct was transfected in K562 cells
and luciferase activity was determined before and after TPA or
hemin treatment. Interestingly, no significant induction of the
reporter activity could be detected after erythroid or megakar-
yocyte differentiation of K562 cells, thus suggesting a rela-
tionship between the ability to undergo endoreplication and
TPA-driven stimulation of cdc6 promoter activity.
To assess the involvement of Esg-specific E2 boxes on cdc6
transcriptional regulation, a 1.7 kb fragment containing
all three sites was deleted and the resulting pHsCdc6–
luc(2800) construct was transfected in HEL, HEL(Esg+)
and K562 cells. Luciferase activity was then measured in
undifferentiated, TPA- and hemin- treated cell extracts
(Figure 2C). While hemin treatment did not result in any
induction of luciferase activity, the transcriptional activity
of this promoter region was increased at a same extent in
all three lines after TPA treatment although no relationship
with the ability of the cell to undergo endoreplication could
be drawn. Similar results were obtained with pHsCdc6–
luc(1600), a deletion construct containing the E2F-binding
elements responsible for cell-cycle-dependent cdc6 expression
regulation and lacking the E2 boxes corresponding to much
less specific Esg binding sites at 1567 to 1561 and at
2675 to 2679 (data not shown).
These results suggest that the 4537 to 2800 region con-
taining the Esg-specific E2 boxes could be responsible for
endoreplication-driven stimulation of cdc6 promoter activity
and that Esg could be responsible for its inhibition when over-
expressed in HEL cells.
In order to explore this hypothesis, a 1.7 kb fragment con-
taining 4537 to 2800 of cdc6 50 upstream region (only
containing Esg-specific E2 boxes A, B and C), was inserted
into a luciferase reporter vector under the control of the SV40
promoter [pHscdc6 (4537/2800)]. This fragment was then
transfected into HEL, HEL(Esg+) and K562 cells. As seen in
Figure 2D, this upstream region of cdc6 gene lacked any
detectable transcriptional activity in exponentially growing
cells. However, after TPA treatment, this fragment was able
to drive luciferase expression in all three lines. Interestingly,
the degree of transcriptional activation was much higher in
endoreplicating HEL than in non-endoreplicating HEL(Esg+)
and K562 cells. Additionally, transcriptional activity of this
1.7 kb fragment was associated with megakaryocytic differ-
entiation only, since no relevant luciferase activity could be
detected in HEL, HEL(Esg+) or K562 cells that underwent
erythrocytic differentiation in the presence of hemin.
Taken together, these results suggest that cdc6 promoter
activity is induced in endoreplicating HEL cells and that
Esg-specific E2 boxes located at 4537 to 2800 may be
critical for such a transcriptional regulation.
Escargot preferentially binds one of three E2 boxes
located in the 50 upstream region of cdc6 gene
We hypothesized whether Esg would bind E2 boxes A, B and
C present in 4537 to 2800 enhancer region ‘in vitro’. HEL
and HEL(Esg+) cells were cultured in the presence or the
absence of TPA and collected 48 h later to isolate nuclear
extracts. At this time of differentiation, HEL cells were act-
ively undergoing endoreplication cycles, which takes place up
to 4 days (Figure 3A) and even up to 1 week (data not shown).
Nuclear extracts were then analyzed by electrophoretic
mobility shift assays (EMSA) using labeled double-stranded
oligonucleotides containing E2 boxes A, B or C, and 9–11
surrounding nucleotides (Box A, Box B and Box C, as shown
in Figure 3B). An oligonucleotide containing the consensus
ACAGGTG binding site for Esg (hereafter referred to as the
Esg Binding Element, EBE) was also included as a positive
control. As already described (8), Esg present in HEL(Esg+)
nuclear extracts results in a specific pattern of two main, spe-
cific shifted bands when complexed with EBE (Figure 3B,
lanes 1 and 2). When HEL(Esg+) nuclear extracts were incu-
bated with Box A, Box B and Box C (Figure 3B, lanes 3–8),
Esg complexes were prominently observed with Box B but
barely detected with Boxes A and C. The pattern of shifted
proteins was very similar in control and TPA differentiated
HEL(Esg+). Thus, it appears that Esg is able to bind, at least
‘in vitro’, to one out of three putative binding sites in cdc6 50
upstream region. In addition, two main extra bands (com-
plexes I and II) were detected to bind Box B, but not EBE,
suggesting the existence of endogenous nuclear factors that
would also bind Box B. To test this, EMSA was then per-
formed with nuclear extracts from parental TPA-untreated and
-treated HEL cells. As observed in the Esg-expressing cells,
binding to Box B was most prominent than to Boxes A and C,
and indeed EBE. More interestingly, complexes I and II were
also detected to bind Box B while as expected, no Esg com-
plexes were present (Figure 3D). Thus, it appears that HEL
cells contain endogenous factors that also recognize this site.
Endogenous nuclear factors specifically bind the
E2 box and an overlapping GATA site
at 3535/3529 of cdc6 promoter
As Box B seemed to contain the most preferred DNA binding
site for ectopic Esg, as well as for the putative endogenous
nuclear factors, we wanted to confirm their binding specificity
through competition experiments with unlabeled Box B, using
extracts from HEL(Esg+) cells. Examination of Box B se-
quence revealed the existence of a GATA motif overlapping
the described E2 box, which prompted us to perform binding
assays on Box B in the presence of unlabeled BEboxM or
BGATAM mutated oligonucleotides, as well as with an unre-
lated oligo containing four E2 boxes in tandem (E2 box
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tandem) (Figure 4A). First, competition with an excess of
unlabeled Box B indicated that not only Esg but also the
endogenous complexes I and II were specific (Figure 4B).
Second, competition with an excess of unlabeled BEboxM,
BGATAM or E2 box tandem revealed that: (i) Esg binds
through the E2 box, since it was only competed with the oligos
containing a wild-type E2 box (BGATAM and E2 box tan-
dem), but not with the BEboxM; (ii) complex II binds through
the GATA motif and does not require the E2 box, as it only
competes with the oligo that contains wild-type GATA bind-
ing site (BEboxM); (iii) complex I binds through the E2 box,
but also requires the surrounding intact GATA motif, since it
competes with oligos containing intact E2 boxes (E2 box
tandem), but not with the oligos containing either a mutated
E2 box (BEboxM) or the mutated GATA motif (BGATAM).
In order to further characterize the complexes binding
requirements, in particular that of complex I, we performed
EMSA analysis to determine the binding pattern to mutated
oligos BEboxM and BGATAM (Figure 4C and D, respect-
ively). As can be observed, only complex II could bind the
oligo containing the mutated E2 box (Figure 4C). This is in
agreement with complex II requiring only GATA motif and
complex I requiring an intact E2 box, as it was also observed
with Escargot. Inversely, only Esg complexes could be
detected when labeled oligo BGATAM was used
(Figure 4D). Thus, this further strengthened the observation
that complex I requires both intact E2 box and GATA motifs
to bind to Box B.
To further confirm the specificity of endogenous complexes,
competition experiments were carried out with nuclear
extracts from parental HEL cells, untreated or TPA differen-
tiated. As shown in Figure 4E, the specificity of complexes I
and II in both undifferentiated and differentiated cells was
identical to that detected in HEL(Esg+) cells.
These results indicate that at least two endogenous com-
plexes are present in HEL cells before and after TPA treat-
ment: complex I which binds the E2 box, but requires intact
adjacent GATA sequence and complex II which specifically
binds to and only requires GATA motif.
GATA-1 and E2A proteins bind to the E2 box/GATA
site ‘in vitro’ and ‘in vivo’
In an attempt to identify endogenous factors contained
in complexes I and II, we investigated whether individual
proteins with specific ability to bind the E2 box/GATA
motif were involved in the binding to Box B site. One obvious
candidate was GATA-1, since this protein is expressed
in megakaryoblastic cells and affects megakaryocytic devel-
opment. On the other hand, an independent one-hybrid
experiment aimed to look for putative endogenous factors
that would bind the EBE element allowed us to identify
E2A (both E12 and E47) and E2-2 bHLH proteins as endo-
genous factors recognizing the G/ACAGGTG E2 box (N. V.
and C. C., unpublished data). Thus, EMSA analysis was per-
formed using HEL nuclear extracts in the presence or absence
Figure 3. Esg and endogenous factors preferentially bind the E2 box/GATA site located at 3535/3525 upstream cdc6 gene. (A) HEL and HEL(Esg+) were
cultured in the absence () or in the presence (+) of 108 M TPA for 48 or 96 h as indicated. DNA content pattern of these cells is shown as analyzed by flow
cytometry. Vertical axis, relative number of cells; horizontal axis, relative red fluorescence (FL2) in a logarithmic scale, indicating DNA content per cell.
(B) Synthetic oligonucleotides corresponding to the EBE, Box A, Box B and Box C used for EMSAs. (C) Nuclear extracts obtained from HEL(Esg+) cells
cultured in the absence () or in the presence (+) of TPA were incubated with labeled EBE, Box A, Box B or Box C and analyzed using EMSA. (D) Nuclear extracts
obtained from HEL cells cultured in the absence () or in the presence (+) of TPA were incubated with labeled EBE, Box A, Box B or Box C and analyzed using
EMSA. Arrows indicate I, II and Esg complexes, as well a non-specific complex (ns).
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of specific antibodies against these proteins. As shown in
Figure 5A, complex II faced severe competition in the pres-
ence of anti GATA-1 antibody, whereas no effect was detected
with an equivalent amount of non-immune serum, or a GATA-
2 antibody. Also, pre-incubation with antiE2A antibody, but
not with non-immune serum, resulted in downregulation of
complex I (Figure 5B).
These results suggest that while Esg binds the E2 box
motif, E2A bHLH factors could be part of the E2 box
binding complex I, dependent on the intact E2 box/GATA
sequence of Box B site. On the other hand, GATA-1 contain-
ing complex II would bind the GATA motif, as illustrated in
Figure 5C.
Owing to the ‘in vitro’ nature of EMSA experiments, we
hypothesized whether the endogenous proteins were bound to
the E2 box/GATA site ‘in vivo’. Chromatin Immunoprecipita-
tion (ChIP) experiments were then performed by isolating
cross-linked chromatin from HEL nuclear extracts. Both
anti-GATA-1 and anti-E2A antibodies, as well as the corre-
sponding non-immune Ig controls, were used to immuno-
precipitate the fragmented chromatin and after reversal of
the cross-link, PCR was performed to detect the presence
of the E2 box/GATA site of cdc6 upstream region. As can
be seen in Figure 5D, in both anti-GATA-1 and anti-E2A
immunoprecipitated fractions, a 249 bp band corresponding
to the expected amplimer for this site could be detected,
whereas no amplification was obtained in the non-immune
Ig-precipitated fractions. A similar specific presence of site
B could be detected with two independent anti-GATA-1 an-
tibodies. Anti-GATA-1, unlike anti-E2A, antibodies were also
able to immunoprecipitate a fragment corresponding to a re-
gion of gamma-globin promoter, already shown to bind
GATA-1 (25). No amplified DNA was obtained when PCR
was performed using primers located approximately 2000
upstream cdc6 promoter. Both GATA-1 and E2A binding to B
site could also be detected when ChIP was performed in HEL
cells treated with TPA (Figure 5E), indicating that both pro-
teins are bound to the endogenous regulatory site in differen-
tiated cells. Similar results were obtained with TPA-treated
and -untreated HEL(Esg+) cells (Figure 5E).
These data indicate that GATA-1 and E2A proteins are able
to bind the E2 box/GATA site ‘in vivo’.
Figure 4. Endogenous nuclear factors require both E2 box and GATA motifs to bind the 3535/3525 E2 box/GATA site. (A) Synthetic oligonucleotides
corresponding to Box B, Box B EboxM, Box B GATAM and the E2 box tandem used for EMSAs. E2 box appears in boldface and GATA site is boxed. Asterisks show
nucleotide modified to obtain mutant E2 box and GATA elements. Esg-specific E2 boxes are marked with a line on the E2 box tandem oligonucleotide. (B) Nuclear
extracts from HEL(Esg+) cells were incubated with labeled Box B in the absence (None) or the presence of an excess of unlabelled Box B (B), Box B EboxM (B
EboxM), Box B GATAM (B GATAM) or E2 box tandem (25 and 50 times, as indicated) and analyzed using EMSA. (C and D) Binding reactions were carried out with
the following labeled oligonucleotides: Box B EboxM (C) or Box B GATAM (D) in the absence () or the presence of 50-fold excess of unlabeled Box B, Box B
EboxM or Box B GATAM. A reaction containing labeled Box B is shown in the first lane of both (C) and (D) as a control. Arrows indicate I, II and Esg complexes, as
well a non-specific complex (ns). (E) Nuclear extracts from HEL cells cultured in the absence () or in the presence (+) of TPA were incubated with labeled Box B in
the absence (None, lanes 1 and 2) or the presence of 50-fold excess of unlabeled Box B (lanes 3–4), Box B EboxM (lanes 5 and 6) or Box B GATAM (lanes 8 and 9) and
analyzed using EMSA. For comparison purposes, nuclear extracts from HEL(Esg+) cells were incubated with labeled Box B (*, lane 7).
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The enhancer activity of 4537 to 2800 cdc6 50
upstream region in megakaryocytic endoreplicating
cells is mainly mediated though the E2 box/
GATA-binding motif
We next hypothesized whether the E2 box overlapping a
GATA motif was implicated in HEL endoreplication-driven
enhancer activity displayed by the entire 1.7 kb fragment.
Mutations at the E2 box as well as at GATA-binding element
in site B were then introduced in pHscdc6 (4537/2800).
The resulting plasmids (BEboxM and BGATAM) as well as the
wild-type construct (Figure 6A) were transfected in HEL,
HEL(Esg+) and K562 cells and luciferase activation was
determined in TPA-treated and -untreated cells. As already
observed, TPA treatment of cells transfected with the wild-
type construct resulted in upregulation of its reporter activity
in all three lines and the degree of transcriptional activation
was highest in the endoreplicating HEL (Figure 6B). However,
the introduction of mutations in the E2 box or the GATA
motifs provoked significant changes in the TPA-promoted
reporter activity. Thus, the construct containing the E2 box
mutation led to a 50% decrease in TPA-promoted inducibility
of the 1.7 kb fragment in HEL cells. Interestingly, when
BGATAM construct was transfected, a strong loss of
activity was obtained (>80%). It seems therefore that an
intact E2 box-GATA motif is required for optimal enhancer
activity in endoreplicating HEL cells.
As expected from our above findings suggesting that Esg
might be interfering with the transcriptional activation through
the E2 box, transfection of BEboxM construct in HEL(Esg+)
cells resulted in higher TPA induction of reported activity than
the observed with the wild-type version. In fact, the transcrip-
tional activation was almost identical to that obtained in HEL
cells transfected with the same BEboxM construct. Similar to
that observed in HEL cells, transfection of BGATAM construct
in HEL(Esg+) cells caused a severe decrease in TPA promoted
inducibility when compared to the wild-type fragment. Inter-
estingly, comparison of BGATAM reporter activity in HEL
and HEL(Esg+) cells showed the inhibitory effect of Esg, in
accordance with the fact that Esg does not bind through the
GATA binding site. This further strengthens the idea that the
E2 box-GATA motif is mainly responsible for the enhancer
activity displayed by pHscdc6 (4537/2800) in endorepli-
cating cells.
Additionally, we observed that TPA induced luciferase ac-
tivity did not suffer any significant modification when the
BEboxM and the BGATAM constructs were transfected in
non-endoreplicating K562, when compared with the wild-
type fragment. This suggests that this site is only functional
Figure 5. Endogenous GATA-1 and E2A bind the 3535/3525 E2 box/GATA site both in vitro and in vivo. (A) Nuclear extracts from HEL(Esg+) cells were
incubated with labeled Box B in the absence (None) or in the presence of goat anti-GATA-1 antibody (a-GATA1), non-immune goat serum (Goat NI), rabbit anti-
GATA-2 antibody (a-GATA2) or non-immune rabbit serum (Rabbit NI), and analyzed using EMSA. (B) A similar experiment was performed in the presence of
rabbit anti-E2A antibody (a-E2A) or non-immune rabbit serum (Rabbit NI). Arrows show complexes I and II. (C) Schematic representation of the binding
requirements of GATA1, E2 box and Escargot complexes to E2 box/GATA motif. (D) ChIP assay was performed using fragmented cross-linked chromatin from HEL
cells and anti-GATA-1 antibodies, aG (Goat C20, or Rat N6), anti-E2A antibody, aE (RabbitV18) or the corresponding non-immune immunoglobulins, NI. One-
sixth of total purified DNA was amplified by PCR with primers specific for the fragment including the E2 box-GATA site (Cdc6 E2 box/GATA) as well as an
unrelated fragment (Cdc6-2000) of cdc6 upstream region. A fragment in the A-g-globin locus (g-globin), is included as a positive control. PCRs were also performed
using the fragmented chromatin purified prior to antibody incubation (Input). (E) ChIP assays were performed using fragmented cross-linked chromatin from HEL
and HEL(Esg+) cells cultured in the absence () or in the presence (+) of TPA and non-immune goat or rabbit Ig (NI), goat anti-GATA-1 (a-G) or rabbit anti-E2A
antibodies (a-E).
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in HEL cells and that it is related to their ability to undergo
endoreplication.
Altogether, these results show that the 4537 to 2800
region of cdc6 upstream region can be considered as an enhan-
cer that activates cdc6 expression in an endoreplication-related
manner during megakaryocytic differentiation and that this is
mainly mediated by the E2 box/GATA motif.
GATA-1 displays a distinct binding pattern to
the 3535/3525 E2 box/GATA site, depending on
the cells ability to undergo endoreplication
As mentioned earlier, both HEL and K562 cells respond
to TPA in terms of megakaryocytic differentiation, although
only HEL cells become polyploid (7). Interestingly, TPA
treatment results in downregulation of cdc6 gene expression,
at both RNA and protein level, in K562 cells, whereas its
expression is maintained in HEL cells (11). Furthermore,
the TPA-promoted enhancer activity of the 1.7 kb fragment
containing 4537 to 2800 of cdc6 50 upstream region con-
taining the E2 box-GATA site was diminished when compared
to HEL cells (see Figure 2D) and was not affected when E2
boxM and GATAM constructs were transfected in K562 cells.
We first investigated whether extracts from these cells would
bind this motif, as observed for HEL and if so, whether they
would present differences in the pattern of proteins able to
bind the E2 box/GATA site of cdc6 upstream region when
differentiated with TPA treatment. EMSA was then performed
on nuclear extracts from K562 cells and, as observed in HEL
cells, binding to Box B was most prominent than to Boxes A
and C (Figure 7A). As shown in Figure 7B, nuclear extracts
Figure 7. Non-endoreplicating K562 cells show additional GATA-1-
containing complexes after megakaryocytic differentiation. (A) Nuclear
extracts obtained from exponentially growing K562 cells were incubated
with labeled Box A, Box B or Box C oligonucleotides and analyzed by
EMSA. (B) Nuclear extracts from K562 cells cultured in the absence () or
in the presence (+) of TPA were incubated with labeled Box B in the absence
(None, lanes 1 and 2) or in the presence of 50-fold excess of unlabeled Box B
(lanes 3 and 4), Box B EboxM (lanes 5 and 6) or Box B GATAM (lanes 8 and 9)
and analyzed using EMSA. For comparison purposes, nuclear extracts from
HEL(Esg+) cells were incubated with labeled Box B (*, lane 7). (C) Nuclear
extracts from K562 cells cultured in the absence () or in the presence (+) of
TPA were incubated with labeled Box B EboxM or Box B and analyzed using
EMSA. (D) Nuclear extracts from TPA-treated K562 cells were incubated with
labeled Box B in the absence (None) or the presence of goat anti-GATA-1
antibody (a-GATA1) or non-immune goat serum (NI) and analyzed using
EMSA. Arrows indicate the already described E2A and GATA-1 containing
complexes, as well as GATA-1-containing complex III.
Figure 6. Enhancer activity of 4537 to 2800 cdc6 50 upstream region in
megakaryocytic endoreplicating cells is mainly mediated through the E2 box/
GATA motif. (A) Diagrams of pHscdc6(4537/2800) (wt) and Ebox
(BEboxM) and GATA (BGATAM) mutant constructs. (B) HEL, HEL(Esg+)
and K562 cells were transfected with wild-type or mutant constructs.
Transfected cells were cultured in the absence () or in the presence (+) of
TPA, collected and assayed for luciferase activity. The data represent the
mean – SD of at least three independent experiments.
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from K562 cells treated with TPA for 48 h, showed differences
when compared with TPA-treated HEL cells (see Figure 4E,
lane 2). Thus, although the pattern of GATA-1 and E2A-
containing complexes was present in both undifferentiated
and TPA-treated K562 cells, two extra bands (complex III)
could only be detected in differentiated K562 cells. As seen in
Figure 7B, competition experiments revealed that the speci-
ficity of GATA-1 and E2A-containing complexes was ident-
ical to that detected in HEL cells. However, BEboxM
oligonucleotide was able to compete in the binding of complex
III to BEbox. Indeed, complex III remained detectable when
an excess of unlabeled BGATAM oligonucleotide was used as
competitor, indicating that these faster migrating bands con-
tained a protein whose binding to Box B site occurred through
the GATA-binding element. Accordingly, GATA-1 and com-
plex III, but not E2A complex, could be detected when EMSA
was performed with TPA-treated K562 nuclear extracts and
labeled BEboxM oligonucleotide (Figure 7C). In an attempt to
determine whether GATA-1 protein was part of complex III,
supershift experiments were performed with TPA-treated
K562 nuclear extracts. As seen in Figure 7D, the presence
of anti-GATA-1 antibody abolished GATA-1-containing com-
plex, as already described, as well as complex III, suggesting
that complex III contained GATA-1 protein.
Altogether, these results indicate that GATA-1 and E2A
specifically bind the E2 box/GATA motif present in cdc6 50
upstream region in K562 cells, as it occurs in HEL cells. They
also indicate that additional GATA-1 complexes bind to this
motif in non-endoreplicating K562 cells after TPA-promoted
differentiation, when compared to differentiated, endoreplicat-
ing HEL cells.
The pattern of GATA-1- and E2A-containing complexes
that bind the E2 box/GATA site is identical in
megakaryoblastic cells and primary megakaryocytes
In order to determine whether the pattern of binding of endo-
genous nuclear factors to the E2 box/GATA motif is asso-
ciated with megakaryocytic lineage, EMSA experiments were
performed with labeled site B oligonucleotide and nuclear
extracts from different human cell lines. It is worth noting
that only megakaryoblastic cells showed the same character-
istic pattern of shifted proteins. HeLa (epithelial origin) or
U937 (promonocytic) did not contain any detectable complex,
whereas osteosarcoma-derived U2OS, and embryonic kidney
293 contained endogenous proteins able to bind this oligonu-
cleotide, but the pattern of bound proteins was distinct from
that detected in megakaryoblastic HEL, HEL(Esg+) K562
cells (Figure 8A).
We finally investigated whether primary megakaryocytes
contained endogenous nuclear factors were able to bind
‘in vitro’ the E2 box/GATA site. Umbilical cord blood
CD34+ cells were cultured in the presence of thrombopoietin
(Tpo) and the content of megakaryocytes was assessed by flow
cytometry analysis of lineage-specific GpIIIa glycoprotein
(CD61) expression. Typically, >70% of cultured cells were
found to be CD61 positive (Figure 8C, Tpo culture). As can be
seen in Figure 8B, only two retarded, specific bands could be
detected when nuclear extracts from megakaryocytic-enriched
cultured cells were incubated with labeled oligonucleotide B.
Megakaryocytes were further purified by immunoselection
with anti-GpIIb (CD41) antibodies. As shown in Figure 8C,
separation resulted in >90% of CD61 positive, of which a
significant 30% corresponded to polyploid cells (DNA
content >8N). EMSA was performed with nuclear extracts
isolated from CD41+ cells (MK), as well as from the
MNCs from which they are derived, and that contain blood
cells mainly (>90% lymphocytes and monocytes). The pattern
of complexes bound to oligonucleotide B in MK extracts
(Figure 8D, lanes 1 and 2) was identical to that found in
the corresponding Tpo culture (Figure 8B), and also to that
detected in megakayoblastic HEL cell line (lanes 7 and 8).
No retarded bands were detected in non-megakaryocytic MNC
cells (lane 3). Addition of anti-GATA-1 (lane 5) and anti-E2A
(lane 10) antibodies to nuclear extracts from megakaryocytic-
enriched cultured cells was able to abolish the formation of
complexes II and I, respectively, indicating that these com-
plexes contained E2A and GATA-1. Interestingly, Cdc6
was present in the terminally differentiated primary mega-
karyocytes (Figure 8E).
Taken together, these results indicate that the binding of
E2A and GATA-1 containing complexes to the E2 box/GATA
motif is a characteristic of the megakaryocytic lineage.
DISCUSSION
The data presented in this work indicate that a 1.7 kb fragment
located at 4537 to 2800 bp upstream cdc6 gene is a tran-
scription enhancer active in megakaryocytic but not in ery-
throcytic differentiated cells nor in exponentially growing
cells. We have found that the stimulation of cdc6 promoter
activity during megakaryocytic endoreplication is dependent
on the integrity of a novel cis-regulatory element defined by
an E2 box overlapping a GATA motif (GCAGGTGATAA)
located at 3535/3525. Our data also show evidence that
this motif is recognized ‘in vitro’ and ‘in vivo’ by GATA-1 and
E2A containing complexes that bind the E2 box/GATA site in
a specific manner. Finally, our data indicate that in human
primary megakaryocytes, GATA-1 and E2A transcription fac-
tors are able to bind this motif, at least ‘in vitro’, with identical
pattern to that detected in megakaryoblastic cell lines.
The E2 box/GATA motif in cdc6 upstream region appears
to be critical for the endoreplication-related stimulation of the
promoter activity. First, when either the E2 box or the GATA
elements are mutated, the transcriptional activity of the entire
1.7 kb region is severely impaired. Second, ectopic expression
of transcriptional repressor Esg, which specifically binds the
E2 box element of the E2 box/GATA motif, leads to a signi-
ficant inhibition of the enhancer activity in HEL cells. This
parallels the loss of Cdc6 expression (11) and of endoreplica-
tion ability (8). Interestingly, ectopically expressing mouse
Snail HEL cells, which also have lost the ability to undergo
endomitosis, show identical pattern of binding of nuclear com-
plexes to the E2 box/GATA motif than HEL(Esg+) cells
(N. Vilaboa, R. Bermejo and C. Cale´s, unpublished data).
To our view, it is highly relevant for Esg to interfere with
the transcriptional activity of cdc6 gene in differentiated HEL
cells, especially as such inhibitory effect seems to affect the
endogenous gene transcription as well as an exogenous, re-
porter gene. It has recently been reported that mouse Sna can
attenuate the cell cycle in epithelial MDCK cells, as well as in
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early embryo development, through partial repression of
cyclin D2 promoter activity (26). Esg does not affect cell
cycle progression in proliferating megakaryoblastic HEL
cells (8). In contrast, Esg inhibition of megakaryocytic endor-
eplication seems to be related to its ability to interfere with
transcriptional activity of cdc6 promoter in differentiated HEL
(Esg+) cells.
It has already been described that a CAGGTG E2 box and
a GATA site define a composite, bipartite regulatory element
involved in the regulation of a number of erythrocytic and
megakaryocytic specific promoters (27,28) including
GATA-1 gene itself (29). The formation of a multimeric com-
plex formed by GATA-1, Tal1, E47, Lmo2 and Ldb1A seems
to rely on a specific spacing of 8–10 bp (1 helix turn)
between the E2 box and the GATA motifs (28). The cis-acting
element we have found to direct cdc6 transcription during
megakaryocytic endoreplication appears to be somehow dis-
tinct from that found in promoters of lineage specific genes.
Notably, there is no spacing between the E2 box and GATA
motifs, and in fact they overlap each other. To our knowledge,
this is the first time that this type of E2 box/GATA site is
reported and that a differentiation-related role in transcrip-
tional control of a licensing factor involved in polyploidization
regulation assigned to such a cis-regulatory element. It is also
highly relevant that an identical E2 box/GATA motif was also
found in the mouse cdc6 gene locus, although in the 30 untrans-
lated end of the gene instead of the upstream region, and a
similar E box/GATA motif in a similar position of the 50 end of
the rat locus (Figure 9). This suggests that similar mechanisms
Ebox-GATA element CANNTGATAR
H.Sapiens (-3556) GCAGGTGATAA(-3546)
(-5942)GCACTTGATAG(-5932)R.Norvegicus
M.Musculus (+22974)GCAGGTGATAG(+22984)
Figure 9. A Ebox-GATA element is present in cdc6 locus of mouse and rat. In
silico search for the presence of an E2box-GATA motif through50 000 bp of
rat chromosome10 (87 675 000–87 725 000 bp) and mouse chromosome 1 (98
530 000–98 610 000 bp) which spans cdc6 gene and surrounding upstream and
downstream 15 000 bp. Both human and rat elements are located upstream first
exon, whereas mouse element lies in the 30-untranslated region. Numbers refer
to the positions respective to reported first exon.
Figure 8. GATA-1 and E2A containing complexes are characteristic of megakaryocytes. (A) Nuclear extracts from exponentially growing HEL, K562, HEL(Esg+),
HeLa, 293 U937 and U2OS cells were incubated with labeled Box B oligonucleotide and analyzed using EMSA. Arrows indicate E2A and GATA-1 containing
complexes. (B) Nuclear extracts from megakaryocytic-enriched primary human cells (Tpo culture) were incubated with labeled Box B in the absence (None) or the
presence (50·) of a 50-times excess of unlabeled Box B and analyzed using EMSA. (C) MNC isolated from human Umbilical Cord Blood, megakaryocytic-enriched
cells obtained after culture of MNC-derived CD34+ cells in the presence of Tpo (Tpo-culture) and immuno-selected megakaryocytes (CD41+) were labeled with
FITC-conjugated anti-GpIIIa (CD61) antibodies (upper panel) or Propidium Iodide (lower panel) and analyzed using flow cytometry. (D) Nuclear Extracts from
CD41+ cells (MK), MNC and HEL cells untreated (control) or TPA-treated (+TPA), were incubated with labeled Box B and analyzed using EMSA. Lane 2: labeling
reaction was performed with MK extracts in the presence of 50 times excess unlabeled Box B. Lanes 4–6 and 9–11: labelling reaction was performed with MK extracts
in the absence (None) or the presence of non-inmune serum (NI) or the indicated antibodies (a-GATA-1 ora-E2A). (E) Nuclear extracts were obtained from CD41+
and untreated or TPA-treated HEL cells. Proteins were subjected to SDS–PAGE and analyzed by western blotting with anti-cdc6 antibody. A portion of total protein
staining of transferred gel is shown as a loading control.
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may be acting in rodent megakaryocytic polyploidization. The
E2box/GATA element is also present in the human GATA-1
locus at chromosome X (N. V., R. B. and C. C., unpublished
data). This last observation might be indicative of an addi-
tional lineage-specific regulation of GATA-1 expression
during megakaryocytic maturation.
This paper provides the first evidence that E2A and GATA-1
containing complexes, individually or in coordination, could
be regulating cdc6 expression. While both GATA-1 and E2A
have been proposed to affect cell cycle control (30–32), to date
only E2A has been described to directly affect the expression
of cdk inhibitors, such as p21, p15 and p16 (33,34). That cdc6
expression might be specifically controlled during megakar-
yocytic endoreplication by a lineage-specific transcriptional
regulator, such as GATA-1 is reinforced by the earlier pro-
posed implication of this transcription factor in determining
proper megakaryocytic polyploidization (35). For instance,
GATA-1 deficient megakaryocytes do not undergo endo-
mitosis and show evidence of retarded nuclear maturation
(35,36). Moreover, X-linked macrothrombocytopenia is due
to various mutations resulting in GATA-1 lack-of-function
and an increased number of dysplastic micromegakaryocytes
(37,38). Micromegakaryocytes are hypoploid megakaryocytes
(39–41), most probably unable to undergo endoreplication
cycles. Disruption of the GATA binding motif strongly dimin-
ished the cdc6 promoter activity in endoreplicating cells while
mutation of the E2 box decreased it to a lesser extent. This is
in accordance to the reported predominant importance of the
GATA site compared to the E2 box present in the composite
E-box–10 bp GATA element 3.7 kb upstream GATA-1 pro-
moter (29). Also, in a non-megakaryocytic cell type, a tran-
scriptional complex between GATA-4 and a bHLH factor
(dHAND) requires the GATA site to be intact, whereas the
E-box motif is dispensable (42). Finally, it is also worth noting
that the ‘in vitro’ binding of E2A-containing complex to the
E2 box/GATA motif requires an intact GATA site, especially
when it would be expected that the binding of a bHLH protein
took place exclusively through the E2 box element.
One interesting result of this paper is the fact that GATA-1
complexes bound to the E2 box/GATA-1 motif ‘in vitro’ show
significant differences between endoreplicating and non-
endoreplicating differentiated megakaryocytic cells. In par-
ticular, a faster migrating GATA complex is detected in
non-endoreplicating differentiated K562 cells. The enhancer
activity of the E2 box/GATA motif-containing region is highly
reduced in these cells. Certainly, it will be of great interest to
investigate whether GATA-1 forms multimeric complexes
with other proteins during megakaryocytic differentiation
and whether the composition of the complexes and/or post-
translational modifications of GATA-1 are different depend-
ing on the cell ability to endoreplicate. GATA-1 has been
shown to form multimeric complexes with a variety of
other transcription factors (i.e. FOG, EKLF, LMO2, SP1,
CBP and Fli-1) and the resulting complexes can even display
stimulatory or repressive transcriptional activity (43).
We have found that human cell lines of different lineages
contain endogenous factors able to bind this motif, at least
‘in vitro’, and that the resulting complex patterns are distinct
of those found in megakaryoblastic cells. Noteworthy, our
‘in vitro’ experiments indicate that GATA-1 and E2A-
containing complexes are able to bind to the E2 box/GATA
motif present in cultured human primary megakaryocytes,
reinforcing the hypothesis that cdc6 promoter activity could
be regulated by differentiation-related transcription factors
such as E2A and GATA-1.
ACKNOWLEDGEMENTS
We acknowledge Dr Nakamura for the generous gift of
pHscdc6 construct. We also thank Dr Aurora Sanchez
Pacheco for help with ChIP experiments setting and Dr
Miguel Vidal for helpful discussions. This work was supported
by grants PM98-0046 from the Spanish Ministry of Science
and Technology, CAM 08.3/0037/2001 from the ‘Comunidad
Auto´noma de Madrid’ and FIS 01/0090-02 from ‘Fondo de
Investigaciones Sanitarias’ to C.C. N.V. was partly supported
by a Postdoctoral Fellowship from ‘Comunidad Auto´noma de
Madrid’ (Spain).
REFERENCES
1. Edgar,B.A. and Orr-Weaver,T.L. (2001) Endoreplication cell
cycles: more for less, Cell, 105, 297–306.
2. Ravid,K., Lu,J., Zimmet,J.M. and Jones,M.R. (2002) Roads to
polyploidy: the megakaryocyte example. J. Cell Physiol., 190, 7–20.
3. Zimmet,J. and Ravid,K. (2000) Polyploidy: occurrence in nature,
mechanisms, and significance for the megakaryocyte-platelet system.
Exp. Hematol., 1, 3–16.
4. Garcia,P. and Cales,C. (1996) Endoreplication in megakaryoblastic cell
lines is accompanied by sustained expression of G1/S cyclins and
downregulation of cdc25C. Oncogene, 13, 695–703.
5. Zimmet,J.M., Ladd,D., Jackson,C.W., Stenberg,P.E. and Ravid,K.
(1997) A role for cyclin D3 in the endomitotic cell cycle. Mol. Cell. Biol.,
17, 7248–7259.
6. Datta,N.S., Williams,J.L. and Long,M.W. (1998) Differential
modulation of G1-S-phase cyclin-dependent kinase 2/cyclin complexes
occurs during the acquisition of a polyploid DNA content. Cell Growth
Differ., 9, 639–650.
7. Garcia,P., Frampton,J., Ballester,A. and Cales,C. (2000) Ectopic
expression of cyclin E allows non-endomitotic megakaryoblastic K562
cells to establish re-replication cycles. Oncogene, 19, 1820–1833.
8. Ballester,A., Frampton,J., Vilaboa,N. and Cales,C. (2001) Heterologous
expression of the transcriptional regulator escargot inhibits
megakaryocytic endomitosis. J. Biol. Chem., 276, 43413–43418.
9. Fuse,N., Hirose,S. and Hayashi,S. (1994) Diploidy of Drosophila
imaginal cells is maintained by a transcriptional repressor encoded by
escargot. Genes Dev., 8, 2270–2281.
10. Nakayama,H., Scott,I.C. and Cross,J.C. (1998) The transition to
endoreduplication in trophoblast giant cells is regulated by the mSNA
zinc finger transcription factor. Dev. Biol., 199, 150–163.
11. Bermejo,R., Vilaboa,N. and Cales,C. (2002) Regulation of CDC6,
geminin, and CDT1 in human cells that undergo polyploidization.
Mol. Biol. Cell, 11, 3989–4000.
12. Diffley,J.F. and Labib,K. (2002) The chromosome replication cycle.
J. Cell. Sci., 115, 869–872.
13. Fujita,M., Yamada,C., Goto,H., Yokoyama,N., Kuzushima,K.,
Inagaki,M. and Tsurumi,T. (1999) Cell cycle regulation of human CDC6
protein: intracellular localization, interaction with the human mcm
complex, and CDC2 kinase-mediated hyperphosphorylation. J. Biol.
Chem., 274, 25927–25932.
14. Castellano,M.M., del Pozo,J.C., Ramirez-Parra,E., Brown,S. and
Gutierrez,C. (2001) Expression and stability of Arabidopsis CDC6 are
associated with endoreplication. Plant Cell, 13, 2671–2686.
15. Ramos,G.B., de Almeida Engler,J., Ferreira,P.C. and Hemerly,A.S.
(2001) DNA replication in plants: characterization of a cdc6 homologue
from Arabidopsis thaliana. J. Exp. Botany, 52, 2239–2240.
16. Hateboer,G., Wobst,A., Petersen,B.O., Le Cam,L., Vigo,E., Sardet,C.
and Helin,K. (1998) Cell cycle-regulated expression of mammalian
CDC6 is dependent on E2F. Mol. Cell. Biol., 18, 6679–6697.
6466 Nucleic Acids Research, 2004, Vol. 32, No. 21
17. Ohtani,K., Tsujimoto,A., Ikeda,M. and Nakamura,M. (1998) Regulation
of cell growth-dependent expression of mammalian CDC6 gene by the
cell cycle transcription factor E2F. Oncogene, 17, 1777–1785.
18. Yan,Z., DeGregori,J., Shohet,R., Leone,G., Stillman,B., Nevins,J.R. and
Williams,R.S. (1998) Cdc6 is regulated by E2F and is essential for
DNA replication in mammalian cells. Proc. Natl Acad. Sci. USA, 95,
3603–3608.
19. Asano,M. and Wharton,R.P. (1999) E2F mediates developmental and cell
cycle regulation of ORC1 in Drosophila. EMBO J., 18, 2435–2448.
20. de Jager,S.M., Menges,M., Bauer,U.M. and Murra,J.A. (2001)
Arabidopsis E2F1 binds a sequence present in the promoter of
S-phase- regulated gene AtCDC6 and is a member of a multigene
family with differential activities. Plant Mol. Biol., 47, 555–568.
21. Humbert,P.O., Verona,R., Trimarchi,J.M., Rogers,C., Dandapani,S. and
Lees,J.A. (2000) E2f3 is critical for normal cellular proliferation. Genes
Dev., 14, 690–703.
22. Schlisio,S., Halperin,T., Vidal,M. and Nevins,J.R. (2002) Interaction of
YY1 with E2Fs,mediated by RYBP,providesa mechanism for specificity
of E2F function. EMBO J., 21, 5775–5786.
23. Forsberg,C.E., Downs,K.M., Christensen,H.M., Im,H., Nuzzi,P.A. and
Bresnick,E.H. (2000) Developmentally dynamic histone acetylation
pattern of a tissue-specific chromatin domain. Proc. Natl Acad. Sci. USA,
97, 14494–14499.
24. Nieto,M.A. (2002) The snail superfamily of zinc-finger transcription
factors. Nature Rev. Mol. Cell. Biol., 3, 155–166.
25. Duan,Z., Stamatoyannopoulos,G. and Li,Q. (2001) Role of NF-Y in
in vivo regulation of the gamma-globin gene. Mol. Cell. Biol., 21,
3083–3095.
26. Vega,S., Morales,A.V., Ocana,O.H., Valdes,F., Fabregat,I. and
Nieto,M.A. (2004) Snail blocks the cell cycle and confers resistance to
cell death. Genes Dev., 18, 1131–1143.
27. Cohen-Kaminsky,S., Maouche-Chre´tien,L., Vitelli,L., Vinit,M.-A.,
Blanchard,I., Yamamoto,M., Peschle,C. and Romeo,P.-H. (1998)
Chromatin imunoselection defines a TAL-1 target gene. EMBO J., 17,
5151–5160.
28. Wadman,I.A., Osada,H., Grutz,G.G., Agulnick,A.D., Westphal,H.,
Forster,A. and Rabbitts,T.H. (1997) The LIM-only protein Lmo2 is a
bridging molecule assembling an erythroid, DNA-binding complex
which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO
J., 16, 3145–3157.
29. Vyas,P., McDevitt,M.A., Cantor,A.B., Katz,S.G., Fujiwara,Y. and
Orkin,S.H. (1999) Different sequence requirements for expression in
erythroid and megakaryocytic cells within a regulatory element upstream
of the GATA-1 gene. Development, 126, 2799–2811.
30. Peverali,F.A., Ramqvist,T., Saffrich,R., Pepperkok,R., Barone,M.V.
and Philipson,L. (1994) Regulation of G1 progression by E2A and
Id helix–loop–helix proteins. EMBO J., 13, 4291–4301.
31. Dubart,A., Romeo,P.H., Vainchenker,W. and Dumenil,D. (1996)
Constitutive expression of GATA-1 interferes with the cell-cycle
regulation. Blood, 87, 3711–3721.
32. Whyatt,D.J., Karis,A., Harkes,I.C., Verkerk,A., Gillemans,N.,
Elefanty,A.G., Vairo,G., Ploemacher,R., Grosveld,F. and Philipsen,S.
(1997) The level of the tissue-specific factor GATA-1 affects the
cell-cycle machinery. Genes Funct., 1, 11–24.
33. Prabhu,S., Ignatova,A., Park,S.T. and Sun,X.-H. (1997) Regulation of the
expression of cyclin-dependent kinase inhibitor p21 by E2A and Id
proteins. Mol. Cell. Biol., 17, 5888–5896.
34. Pagliuca,A., Gallo,P., De Luca,P. and Lania,L. (2000) Class A
helix–loop–helix proteins are positive regulators of several
cyclin-dependent kinase inhibitors’ promoter activity and negatively
affect cell growth. Cancer Res., 60, 1376–1382.
35. Vyas,P., Ault,K., Jackson,C.W., Orkin,S.H. and Shivdasani,R.A. (1999)
Consequences of GATA-1 deficiency in megakaryocytes and platelets.
Blood, 93, 2867–2875.
36. Shivdasani,R.A., Fujiwara,Y., McDevitt,M.A. and Orkin,S.H. (1997)
A lineage-selective knockout establishes the critical role of transcription
factor GATA-1 in megakaryocyte growth and platelet development.
EMBO J., 16, 3965–3973.
37. Nichols,K.E., Crispino,J.D., Poncz,M., White,J.G., Orkin,S.H.,
Maris,J.M. and Weiss,M.J. (2000) Familial dyserythropoietic anaemia
and thrombocytopenia due to inherited mutation in GATA1. Nature
Genet., 24, 266–270.
38. Freson,K., Matthijs,G., Thys,C., Mari€en,P., Hoylaerts,M.F., Vermylen,J.
and Van Geet,C. (2002) Different substitutions at residue 218 of the
X-linked transcription factor GATA-1 lead to altered clinical severity of
macrothrombocytopaenia and anemia and are associated with variable
skewed X inactivation. Hum. Mol. Genet., 11, 147–152.
39. Hegyi,E., Nakazawa,M., Debili,N., Navarro,S., Katz,A.,
Breton-Gorius,J. and Vainchenker,W. (1991) Developmental changes in
human megakaryocyte ploidy. Exp. Hematol., 19, 87–94.
40. Olson,T.A., Levine,R.F. and Kelleher,J. (1992) Familial
thrombocytopenia with micromegakaryocytes. Am. J. Pediatr. Hematol.
Oncol., 14, 248–254.
41. Levine,R.F., Olson,T.A., Shoff,P.K., Miller,M.K. and Weisman,L.E.
(1996) Mature micromegakaryocytes: an unusual developmental pattern
in term infants. Br. J. Haematol., 94, 391–399.
42. Dai,Y.-S., Cserjesi,P., Markham,B.E. and Molkentin,J.D. (2002) The
transcription factors GATA4 and dHAND physically interact
to synergistically activate cardiac gene expression through
a p300-dependent mechanism. J. Biol. Chem., 277,
24390–24398.
43. Cantor,A.B. and Orkin,S.H. (2002) Transcriptional regulation of
erythropoiesis: an affair involving multiple partners. Oncogene, 21,
3368–3376.
Nucleic Acids Research, 2004, Vol. 32, No. 21 6467
